Download PDF
Thromb Haemost 1991; 66(06): 678-683
DOI: 10.1055/s-0038-1646485
Original Article
Schattauer GmbH Stuttgart

Regulation of the Urokinase Receptor by Its Plasminogen Activator

W Hollas
The Department of Tumor Biology, M. D. Anderson Cancer Center, Houston, USA
,
D Boyd
The Department of Tumor Biology, M. D. Anderson Cancer Center, Houston, USA
› Author Affiliations
Further Information

Publication History

Received 29 January 1991

Accepted 14 June 1991

Publication Date:
26 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

There is now ample evidence that the proteolytic action of urokinase (UK) is potentiated by a specific cell surface receptor. The present study was undertaken to assess the role of UK as a modulator of its receptor. GEO colonic cells, which secrete relatively low levels of UK (≃0.1 nM/72 h per 106 cells) and display approximately 104 receptors per cell, 10% of which are "tagged" with the endogenous plasminogen activator (PA), was selected for the study. A 90% reduction in the specific binding of radioactive DFP-UK was observed for cells cultivated in the presence of two-chain (TC) UK (M r 55,000). This only partly reflected occupation of the receptors with UK supplied in the culture medium, since the specific binding of the radioligand was still reduced by 60% after an acid pretreatment, which dissociates receptor-bound UK. The reduction in radioactive DFP-UK binding to cells treated with high molecular weight UK, either in the single or two-chain form, was both concentration and time dependent. Maximum reductions (70%) were achieved by treatment of the cells for 24 h with 1 nM of the plasminogen activator. In contrast, low molecular weight UK, which lacks part of the UK A chain, had no effect on ligand binding. Attenuation of radioactive DFP-UK binding to UK treated GEO cells was a consequence of a 60% reduction in the number of binding sites. Treatment of GEO cells with an antibody, which blocks the binding of endogenous UK to its receptor, augmented radioactive DFP-UK binding by two-fold. These data indicate that for one colonic cell line, at least, UK down-regulates its own binding site subsequent to it being bound to the receptor.

 

  • References

  • 1 Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65
    PubMedGoogle Scholar
  • 2 Testa J, Quigley J. The role of urokinase-type plasminogen activator in aggregssive tumor cell behavior. Cancer Metastasis Rev 1990; 9: 353-67
    CrossrefPubMedGoogle Scholar
  • 3 Dano K, Andreasen P, Grondahl-Hansen J, Kristensen P, Nielsen L, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
    PubMedGoogle Scholar
  • 4 Robbins K, Summaria K, Hsieh B, Shah R. The peptide chains of human plasmin. J Biol Chem 1967; 242: 2333-42
    PubMedGoogle Scholar
  • 5 Liotta L, Goldfarb R, Brundage R, Siegal G, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-36
    PubMedGoogle Scholar
  • 6 Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990; 50: 5997-6001
    PubMedGoogle Scholar
  • 7 Stoppelli M, Tacchetti C, Cubellis M, Corti A, Hearing V, Cassani G, Appella E, Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45: 675-84
    CrossrefPubMedGoogle Scholar
  • 8 Vassalli J, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92
    CrossrefPubMedGoogle Scholar
  • 9 Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: Dependence on urokinase receptor display. Cancer Comm 1990; 2: 173-9
    PubMedGoogle Scholar
  • 10 Schlechte W, Murano G, Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 1989; 49: 6064-9
    PubMedGoogle Scholar
  • 11 Kirchheimer J, Remold H. Endogenous receptor-bound urokinase mediates tissue invasion by human monocytes. J Immunol 1989; 143: 2634-9
    PubMedGoogle Scholar
  • 12 Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988; 107: 2437-45
    CrossrefPubMedGoogle Scholar
  • 13 Behrendt N, Ronnen E, Ploug M, Petri T, Leber D, Nielsen LS, Wolf-Dieter S, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. J Biol Chem 1990; 11: 6453-60
    PubMedGoogle Scholar
  • 14 Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Sci USA 1985; 82: 4939-43
    CrossrefPubMedGoogle Scholar
  • 15 Roldan A, Cubellis M, Masucci M, Behrendt N, Lund L, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74
    PubMedGoogle Scholar
  • 16 Boyd D. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a colon cancer cell line. Cancer Res 1989; 49: 2427-32
    PubMedGoogle Scholar
  • 17 Boyd D, Brattain MG. Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line. Cancer Res 1989; 49: 1948-53
    PubMedGoogle Scholar
  • 18 Brattain M, Levine A, Chakrabarty S, Yeoman L, Willson J, Long B. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev 1984; 3: 177-91
    CrossrefPubMedGoogle Scholar
  • 19 Chantret I, Barbat A, Dussaulx E, Brattain M, Zweibaum A. Epithelial polarity, villin expression and enterocytic differentiation of cultured colon carcinoma cells: A survey of twenty cell lines. Cancer Res 1988; 48: 1936-42
    PubMedGoogle Scholar
  • 20 Boyd D, Levine AE, Brattain DE, McKnight MK, Brattain MG. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res 1988; 48: 2469-74
    PubMedGoogle Scholar
  • 21 Boyd D, Florent G, Kim P, Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988; 48: 3112-6
    PubMedGoogle Scholar
  • 22 Bajpai A, Baker J. Urokinase binding sites on human foreskin cells. Biochem Biophys Res Commun 1985; 133: 9940-10000
    PubMedGoogle Scholar
  • 23 Darras V, Thienpont M, Stump D, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 1986; 56: 411-4
    PubMedGoogle Scholar
  • 24 Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-72
    CrossrefPubMedGoogle Scholar
  • 25 Cubellis M, Wun T, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990; 9: 1079-85
    PubMedGoogle Scholar
  • 26 Schlechte W, Boyd DD. Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer. Cancer Comm 1990; 2: 261-70
    PubMedGoogle Scholar
  • 27 Andreasen P, Nielsen L, Kristensen P, Grondahl-Hansen J, Skriver L, Dano K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986; 261: 7644-51
    PubMedGoogle Scholar
  • 28 Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: Catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989; 74: 1396-402
    PubMedGoogle Scholar
  • 29 Ellis V, Scully MF, Kakkar W. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. J Biol Chem 1989; 264: 2185-8
    PubMedGoogle Scholar
  • 30 Krupp M, Connolly D, Lane M. Synthesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts. J Biol Chem 1982; 257: 11489-96
    PubMedGoogle Scholar
  • 31 Garrett J, Coughlin S, Niman H, Tremble P, Giels G, Williams L. Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors. Proc Natl Acad Sci 1984; 81: 7466-70
    CrossrefPubMedGoogle Scholar
  • 32 Hoeck W, Rusconi S, Groner B. Down-regulation and phosphorylation of glucocorticoid receptors in cultured cells. J Biol Chem 1989; 264: 14396-402
    PubMedGoogle Scholar
  • 33 Reynet C, Caron M, Magre J, Cherqui G, Clauser E, Picard J, Chapeau J. Mutation of tyrosine residues 1162 and 1163 of the insulin receptor affects hormone and receptor internalization. Mol Endocrinol 1990; 4: 304-11
    CrossrefPubMedGoogle Scholar
  • 34 Honegger A, Dull T, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A, Schlessinger J. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 1987; 51: 199-209
    CrossrefPubMedGoogle Scholar
  • 35 Plough M, Ronne E, Behrendt N, Jensen A, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. J Biol Chem 1991; 266: 1926-33
    PubMedGoogle Scholar
  • 36 Picone R, Kajtaniak E, Nielsen L, Behrendt N, Mastronicola M, Cubellis M, Stoppelli M, Pedersen S, Dano K, Blasi F. Regulation of urokinase receptors in monocyte-like U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 1989; 108: 693-702
    CrossrefPubMedGoogle Scholar
  • 37 Boyd D, Florent G, Murano G, Brattain M. Modulation of the urokinase receptor in human colon cell lines by N,N-dimethyl-formamide. Biochim Biophys Acta 1988; 947: 96-100
    PubMedGoogle Scholar
  • 38 Kirchheimer J, Nong Y, Remold H. IFN-gamma, tumor necrosis factor a and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol 1988; 141: 4229-34
    PubMedGoogle Scholar
  • 39 Blasi F, Stoppelli P, Cubellis M. The receptor for urokinase-plasminogen activator. J Cell Biol 1986; 32: 179-86
    CrossrefPubMedGoogle Scholar